# Tafasitamab in refractory diffuse large B-cell lymphoma with neurolymphomatosis

## TL;DR

A new treatment using tafasitamab and lenalidomide successfully treated a rare nerve-involving lymphoma in an elderly patient.

## Contribution

First demonstration of tafasitamab's efficacy in neurolymphomatosis with full recovery and minimal side effects.

## Key findings

- Tafasitamab and lenalidomide achieved complete remission in a DLBCL patient with neurolymphomatosis.
- The treatment resulted in full neurological recovery with minimal side effects.
- This regimen is a promising option for frail patients unsuitable for intensive therapies.

## Abstract

Peripheral nervous system involvement in lymphoproliferative diseases, often due to direct nerve infiltration (neurolymphomatosis, NL), is mostly seen in aggressive B-cell lymphoma. We report the case of an 88-year-old man with stage IVA DLBCL, who achieved the first complete response after six R-miniCHOP21 cycles. One year post-treatment, he developed severe neurological symptoms, and PET-CT revealed widespread relapse with extensive neural involvement. Treatment with tafasitamab and lenalidomide led to a complete morpho-metabolic remission and full neurological recovery, with minimal side effects. This case underscores for the very first time the efficacy and tolerability of this regimen in treating NL, highlighting its potential for frail patients unfit for more intensive therapies.